Subscribe To
COCP / Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
COCP News
By Benzinga
April 12, 2022
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemi more_horizontal
By Benzinga
January 27, 2022
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. more_horizontal
By Benzinga
January 27, 2022
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. more_horizontal
By Benzinga
January 27, 2022
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. more_horizontal
By GlobeNewsWire
October 6, 2021
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biote more_horizontal
By GlobeNewsWire
October 6, 2021
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biote more_horizontal
By GlobeNewsWire
October 6, 2021
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biote more_horizontal